+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dual Targeted Therapy Market by Type, Application, End User, Drug Administration Route, Therapy Mechanism - Global Forecast 2025-2030- Product Image
Dual Targeted Therapy Market by Type, Application, End User, Drug Administration Route, Therapy Mechanism - Global Forecast 2025-2030- Product Image
Sale

Dual Targeted Therapy Market by Type, Application, End User, Drug Administration Route, Therapy Mechanism - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6015556
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dual Targeted Therapy Market grew from USD 283.30 million in 2023 to USD 361.28 million in 2024. It is expected to continue growing at a CAGR of 26.67%, reaching USD 1.48 billion by 2030.

Dual targeted therapy refers to medical treatments that simultaneously target two specific pathways or molecules involved in disease progression, primarily used in oncology to manage and treat cancer by attacking multiple targets within tumor cells or the tumor microenvironment. The necessity for dual targeted therapy emerges from the complexity of diseases like cancer, where single-target therapies often lead to resistance or suboptimal efficacy. These therapies are increasingly applied in precision medicine, where treatments are tailored to the genetic profile of both the patient and the tumor, enhancing efficacy and patient outcomes. The end-use scope encompasses hospitals, cancer research centers, and biopharmaceutical companies, highlighting its relevance in research and clinical settings.

Market growth is significantly influenced by advancements in biotechnology, expanding cancer patient populations, and increased funding for cancer research. Precision medicine’s rise and growing awareness about personalized therapies are key drivers. Opportunities lie in expanding applications beyond oncology, such as autoimmune diseases, and leveraging technological advancements like CRISPR for developing novel therapeutic combinations. However, challenges persist, including high R&D costs, regulatory hurdles, and the complexity of developing therapies that effectively and safely target multiple pathways.

Innovation and research can be directed towards identifying new molecular targets and developing bispecific antibodies or combination therapies that enhance patient-specific treatment. Biopharmaceutical companies should focus on next-generation sequencing (NGS) technologies to uncover genetic variations linked to disease resistance to existing therapies. Collaborative efforts between academic institutions and pharmaceutical companies can accelerate discovery and development processes. The market is fast-evolving, driven by technological innovation, but the competitive landscape is marked by rapid advancements and emerging startups challenging traditional big pharma players. Businesses can achieve growth by investing in robust pipelines of dual targeted therapies, pursuing strategic partnerships, and acquiring companies with complementary technologies or those leading in niche markets within dual therapy applications.

Understanding Market Dynamics in the Dual Targeted Therapy Market

The Dual Targeted Therapy Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising collaborative efforts between biotech companies and academic institutions to develop novel targeted therapies
    • Rapid advancements in biotechnology and genomics enhancing the efficacy and safety profiles of therapies
    • Expansion of healthcare infrastructure and accessibility in emerging markets boosting therapy uptake
    • Increased regulatory support for fast-tracking the approval process of breakthrough therapies
  • Market Restraints
    • High development costs and financing barriers in dual-targeted therapy treatment
  • Market Opportunities
    • Development of dual targeted therapies for rare and orphan diseases
    • Expansion of dual targeted therapy applications in oncology
    • Integration of AI and machine learning in the development of dual targeted therapies
  • Market Challenges
    • Regulatory hurdles and compliance issues in dual-targeted therapy

Exploring Porter’s Five Forces for the Dual Targeted Therapy Market

Porter’s Five Forces framework further strengthens the insights of the Dual Targeted Therapy Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Dual Targeted Therapy Market

External macro-environmental factors deeply influence the performance of the Dual Targeted Therapy Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Dual Targeted Therapy Market

The Dual Targeted Therapy Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Dual Targeted Therapy Market

The Dual Targeted Therapy Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Dual Targeted Therapy Market

The Dual Targeted Therapy Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dual Targeted Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Incyte Corporation, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Syndax Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Dual Targeted Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Combination Therapy
      • Biologic Combinations
      • Small Molecule and Biologic Combinations
      • Small Molecule Combinations
    • Single Drug Therapy
  • Application
    • Autoimmune Diseases
      • Multiple Sclerosis
      • Rheumatoid Arthritis
    • Cardiovascular Diseases
      • Coronary Artery Disease
      • Heart Failure
      • Hypertension
    • Infectious Diseases
      • Bacterial Infections
      • Viral Infections
    • Oncology
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
      • Prostate Cancer
  • End User
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Drug Administration Route
    • Intramuscular
    • Intravenous
    • Oral
    • Subcutaneous
  • Therapy Mechanism
    • Immunotherapy
    • Targeted Therapy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising collaborative efforts between biotech companies and academic institutions to develop novel targeted therapies
5.1.1.2. Rapid advancements in biotechnology and genomics enhancing the efficacy and safety profiles of therapies
5.1.1.3. Expansion of healthcare infrastructure and accessibility in emerging markets boosting therapy uptake
5.1.1.4. Increased regulatory support for fast-tracking the approval process of breakthrough therapies
5.1.2. Restraints
5.1.2.1. High development costs and financing barriers in dual-targeted therapy treatment
5.1.3. Opportunities
5.1.3.1. Development of dual targeted therapies for rare and orphan diseases
5.1.3.2. Expansion of dual targeted therapy applications in oncology
5.1.3.3. Integration of AI and machine learning in the development of dual targeted therapies
5.1.4. Challenges
5.1.4.1. Regulatory hurdles and compliance issues in dual-targeted therapy
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Dual Targeted Therapy Market, by Type
6.1. Introduction
6.2. Combination Therapy
6.2.1. Biologic Combinations
6.2.2. Small Molecule and Biologic Combinations
6.2.3. Small Molecule Combinations
6.3. Single Drug Therapy
7. Dual Targeted Therapy Market, by Application
7.1. Introduction
7.2. Autoimmune Diseases
7.2.1. Multiple Sclerosis
7.2.2. Rheumatoid Arthritis
7.3. Cardiovascular Diseases
7.3.1. Coronary Artery Disease
7.3.2. Heart Failure
7.3.3. Hypertension
7.4. Infectious Diseases
7.4.1. Bacterial Infections
7.4.2. Viral Infections
7.5. Oncology
7.5.1. Breast Cancer
7.5.2. Colorectal Cancer
7.5.3. Lung Cancer
7.5.4. Prostate Cancer
8. Dual Targeted Therapy Market, by End User
8.1. Introduction
8.2. Hospitals
8.3. Research Institutes
8.4. Specialty Clinics
9. Dual Targeted Therapy Market, by Drug Administration Route
9.1. Introduction
9.2. Intramuscular
9.3. Intravenous
9.4. Oral
9.5. Subcutaneous
10. Dual Targeted Therapy Market, by Therapy Mechanism
10.1. Introduction
10.2. Immunotherapy
10.3. Targeted Therapy
11. Americas Dual Targeted Therapy Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Dual Targeted Therapy Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Dual Targeted Therapy Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. DUAL TARGETED THERAPY MARKET RESEARCH PROCESS
FIGURE 2. DUAL TARGETED THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2023 VS 2030 (%)
FIGURE 15. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. DUAL TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. DUAL TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. DUAL TARGETED THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. DUAL TARGETED THERAPY MARKET DYNAMICS
TABLE 7. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE AND BIOLOGIC COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SINGLE DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 77. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 78. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 79. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 81. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 82. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 83. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 84. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 86. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 87. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 89. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 91. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 92. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 93. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 94. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 119. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 129. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 130. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 131. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 133. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 134. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 135. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 136. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 138. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 139. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 141. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 143. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 144. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 145. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 146. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 148. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 149. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 150. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 151. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 159. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 160. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 161. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 163. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 164. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 165. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 166. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 168. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 169. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 170. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 179. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 180. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 181. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 189. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 190. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 191. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 209. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 210. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 211. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 218. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 219. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 220. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 221. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 223. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 224. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 225. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 226. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 228. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 238. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 250. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 251. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 252. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 254. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 255. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 256. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 257. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 259. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 260. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 261. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 262. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 264. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 265. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 266. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 267. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 269. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 270. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 271. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 272. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 274. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 275. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 276. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 277. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 279. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 280. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 281. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 282. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 283. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 284. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 285. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 286. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 287. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 289. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 290. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 291. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 292. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 294. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 295. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 296. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 297. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 299. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 307. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 310. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 311. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 312. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 313. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 314. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 315. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 316. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 317. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 319. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
TABLE 320. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 321. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 322. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 323. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 324. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 325. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 326. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 327. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 328. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 329. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (

Companies Mentioned

The leading players in the Dual Targeted Therapy Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Syndax Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 361.28 Million
Forecasted Market Value ( USD ) by 2030 $ 1480 Million
Compound Annual Growth Rate26.6%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Bispecific Antibodies Market by Mechanism of Action, Therapeutic Area, End-user - Global Forecast 2025-2030 - Product Image

Bispecific Antibodies Market by Mechanism of Action, Therapeutic Area, End-user - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024 - Product Image

Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024

  • Report
  • 50 Pages
  • Global
From
Neoantigen Targeted Therapies Market by Target Disease Indication, Neoantigens Type, Immunotherapy Type, Route of Administration - Global Forecast 2025-2030 - Product Image

Neoantigen Targeted Therapies Market by Target Disease Indication, Neoantigens Type, Immunotherapy Type, Route of Administration - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
CAR T Cell Therapy Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication, Target Antigens, Key Geographical Regions, Key Players and Sales Forecast - Product Image

CAR T Cell Therapy Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication, Target Antigens, Key Geographical Regions, Key Players and Sales Forecast

  • Report
  • 640 Pages
  • Global
From
Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2024 - Product Image

Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2024

  • Report
  • 330 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.